Compare · LIVN vs SMLR
LIVN vs SMLR
Side-by-side comparison of LivaNova PLC (LIVN) and Semler Scientific Inc. (SMLR): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both LIVN and SMLR operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- LIVN carries a market cap of $5.06B.
- LIVN has hit the wire 7 times in the past 4 weeks while SMLR has been quiet.
- LIVN has more recent analyst coverage (21 ratings vs 6 for SMLR).
- Company
- LivaNova PLC
- Semler Scientific Inc.
- Price
- -
- -
- Market cap
- $5.06B
- -
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NASDAQ
- NASDAQ
- IPO
- News (4w)
- 7
- 0
- Recent ratings
- 21
- 6
LivaNova PLC
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates in two segments, Cardiovascular (CV) and Neuromodulation (NM). The CV segment develops, produces, and sells cardiopulmonary products, including heart-lung machines, oxygenators, perfusion tubing sets, cannulae, and accessories, as well as related equipment and disposables for autotransfusion and autologous blood washing for neonatal, pediatric, and adult patients. It also provides surgical tissue and mechanical valve replacements, and repair products for damaged or diseased heart valves, such as self-anchoring tissue heart, tissue heart, and mechanical heart valves, as well as heart valve repair products; and temporary extracorporeal cardiopulmonary life support solutions for critically ill patients. The NM segment designs, develops, and markets VNS Therapy System, an implantable device that delivers vagus nerve stimulation (VNS) therapy for the treatment of drug-resistant epilepsy, difficult-to-treat depression, and obstructive sleep apnea. It is also involved in the development and clinical testing of the VITARIA System for treating heart failure through VNS. The company serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. It sells its products through direct sales representatives and independent distributors. The company has a research collaboration with Verily to capture clinical biomarkers of depression. LivaNova PLC was founded in 1987 and is headquartered in London, the United Kingdom.
Semler Scientific Inc.
Semler Scientific, Inc. develops, manufactures, and markets proprietary products that assist healthcare providers to evaluate and treat patients with chronic diseases in the United States. The company's products include QuantaFlo, a four-minute in-office blood flow test that enables healthcare providers to use blood flow measurements as part of their examinations of a patient's vascular condition. Its products serve cardiologists, internists, nephrologists, endocrinologists, podiatrists, and family practitioners, as well as healthcare insurance plans, integrated delivery networks, independent physician groups, and companies contracting with the healthcare industry, such as risk assessment groups. The company offers its products through salespersons and distributors. Semler Scientific, Inc. was incorporated in 2007 and is headquartered in Santa Clara, California.
Latest LIVN
- Chief Financial Officer Shvartsburg Alex sold $227,275 worth of Ordinary Shares (2,500 units at $90.91) as part of a pre-agreed trading plan, decreasing direct ownership by 6% to 42,147 units (SEC Form 4)
- SEC Form SCHEDULE 13G filed by LivaNova PLC
- Amendment: SEC Form SCHEDULE 13G/A filed by LivaNova PLC
- SEC Form IRANNOTICE filed by LivaNova PLC
- SEC Form 10-Q filed by LivaNova PLC
- LivaNova PLC filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- LivaNova Reports Third-Quarter 2026 Results; Raises Full-Year 2026 Revenue and Adjusted Diluted EPS Guidance
- Neuromodulation Publishes Full 36-Month CORE-VNS Results Demonstrating Sustained and Increasing Benefits of LivaNova’s VNS Therapy for Drug-Resistant Epilepsy
- LivaNova to Present at UBS, Wolfe, Stifel, and Jefferies Healthcare Conferences in November
- Barclays initiated coverage on LivaNova with a new price target
Latest SMLR
- SEC Form SCHEDULE 13G filed by Semler Scientific Inc.
- SEC Form 15-12G filed by Semler Scientific Inc.
- SEC Form EFFECT filed by Semler Scientific Inc.
- SEC Form EFFECT filed by Semler Scientific Inc.
- SEC Form S-8 POS filed by Semler Scientific Inc.
- SEC Form S-8 POS filed by Semler Scientific Inc.
- SEC Form S-8 POS filed by Semler Scientific Inc.
- SEC Form S-8 POS filed by Semler Scientific Inc.
- SEC Form S-8 POS filed by Semler Scientific Inc.
- SEC Form S-8 POS filed by Semler Scientific Inc.